Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$8.48
+0.10 (+1.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $823.0M · quality 80.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.4B
P/E
5.8x
↓EV/EBITDA
-0.3x
↓ROE
11.8%
↑Gross Margin
72.3%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.4%
FCF CAGR
-0.2%
FCF margin
31.1%
FCF / Net income
1.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.14B · net income $949.9M · FCF $974.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.14B | $3.14B | $3.78B | $4.52B | $3.95B |
| Net Income | $949.9M | $949.9M | $840.1M | $969.5M | $722.8M |
| EBITDA | $1.35B | $1.35B | $1.22B | $1.30B | $1.10B |
| EPS | 1.26 | 1.26 | 1.11 | 1.28 | 0.96 |
| Gross Margin | 72.3% | 72.3% | 75.0% | 75.1% | 74.4% |
| Operating Margin | 22.9% | 22.9% | 22.3% | 21.6% | 18.3% |
| Net Margin | 30.3% | 30.3% | 22.2% | 21.5% | 18.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.05 | 0.04 | 0.00 |
| Current Ratio | 3.71 | 3.71 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $974.1M | $974.1M | $823.0M | $788.3M | $980.2M |
| Returns | |||||
| ROE | 11.8% | 11.8% | 11.3% | 13.8% | 11.3% |
| Valuation | |||||
| P/E | 5.77 | 5.77 | 7.79 | 6.04 | 8.13 |
| EV/EBITDA | -0.33 | -0.33 | 0.61 | 0.19 | 0.79 |
| P/B | 0.79 | 0.79 | 0.88 | 0.83 | 0.92 |
| Growth & Yield | |||||
| Revenue Growth | -17.0% | -17.0% | -16.4% | 14.3% | — |
| EPS Growth | 13.5% | 13.5% | -13.3% | 33.3% | — |
| Dividend Yield | 7.2% | 7.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-15.8%
EPS terminal req.
$0.75
Spread vs growth
29.3%
5Y implied EPS CAGR
-6.3%
EPS terminal req.
$0.91
Spread vs growth
19.8%
10Y implied EPS CAGR
1.5%
EPS terminal req.
$1.47
Spread vs growth
12.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+21.8%
Start / end P/E
6.7x → 6.7x
EPS bridge
1.11 → 1.26
Residual
+0.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.